Menu Search
Equities

Pfizer Inc

PFE:DUS

Pfizer Inc

Actions
  • Price (EUR)38.02
  • Today's Change0.48 / 1.28%
  • Shares traded0.00
  • 1 Year change-22.15%
  • Beta--
Data delayed at least 15 minutes, as of Mar 20 2023 20:01 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

  • Revenue in USD (TTM)100.33bn
  • Net income in USD31.37bn
  • Incorporated1942
  • Employees83.00k
  • Location
    Pfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
  • Phone+1 (212) 733-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		PFE:NYQ since
announced		Transaction
value
Seagen IncAnnounced13 Mar 202313 Mar 2023Announced3.60%43.84bn
Global Blood Therapeutics IncDeal completed08 Aug 202208 Aug 2022Deal completed-17.17%5.07bn
Biohaven Pharmaceutical Holding Co LtdDeal completed10 May 202210 May 2022Deal completed-16.10%12.60bn
ReViral LtdDeal completed07 Apr 202207 Apr 2022Deal completed-22.81%525.00m
Data delayed at least 15 minutes, as of Mar 20 2023 20:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.